Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722493 | 0.89 | L3MBTL1 (0.49) | NOS3NOS1NOS2L3MBTL1MAPT | |
| SCHEMBL2351932 | 0.87 | NOS3 (0.56) | NOS3NOS1NOS2L3MBTL1HTR2A | |
| P-Xylene SCHEMBL20836571 | 0.80 | HTR2A (0.56) | NOS3NOS1NOS2L3MBTL1HTR2A | |
| SCHEMBL6546810 | 0.79 | RAB9A (0.50) | NOS3NOS1NOS2L3MBTL1HTR2A | |
| SCHEMBL7819859 | 0.78 | CALM1 (0.48) | L3MBTL1KDM4E | |
| SCHEMBL10930288 | 0.78 | MAOA (0.52) | NOS3NOS1NOS2L3MBTL1HTR2A | |
| SCHEMBL3689999 | 0.78 | MAOA (0.52) | NOS3NOS1NOS2L3MBTL1HTR2A | |
| SCHEMBL2356590 | 0.78 | HTR2A (0.60) | L3MBTL1HTR2APOLBSIGMAR1 | |
| SCHEMBL28385202 | 0.78 | PTGS1 (0.56) | NOS3NOS1NOS2HTR2ANPC1 | |
| SCHEMBL31500446 | 0.77 | TAAR1 (0.61) | NOS3NOS1NOS2HTR2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158233-B1 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | ALBEMARLE CORP (US) | 2018-10-31 | — | — | EP | claimed |
| US-20130210995-A1 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | ALBEMARLE CORPORATION (US) | 2013-08-15 | — | — | US | claimed |
| US-20100184941-A1 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | ALBEMARLE CORPORATION (US) | 2010-07-22 | — | — | US | claimed |
| EP-2158233-A2 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | Albermarle Corporation (US) | 2010-03-03 | — | — | EP | claimed |
| WO-2008154454-A2 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | ALBEMARLE CORPORATION (US) | 2008-12-18 | — | — | WO | claimed |
| EP-2158233-B1 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | ALBEMARLE CORP (US) | 2018-10-31 | — | — | EP | disclosed |
| US-8822743-B2 | Adducts, adducts and oligomers, or adducts, oligomers and low molecular weight polymers, and their preparation | ALBEMARLE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130210995-A1 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | ALBEMARLE CORPORATION (US) | 2013-08-15 | — | — | US | disclosed |
| US-8420876-B2 | Adducts, adducts and oligomers, or adducts, oligomers and low molecular weight polymers, and their preparation | ALBEMARLE CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100184941-A1 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | ALBEMARLE CORPORATION (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2158233-A2 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | Albermarle Corporation (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008154454-A2 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | ALBEMARLE CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-6033529-A | Separation of mesitylene from 4-ethyl toluene by azeotropic distillation | BERG LLOYD (US) | 2000-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184941-A1 | ADDUCTS, ADDUCTS AND OLIGOMERS, OR ADDUCTS, OLIGOMERS AND LOW MOLECULAR WEIGHT POLYMERS, AND THEIR PREPARATION | PCNA, OGG1, DDB1 | NOS3 3047/4885NOS1 3521/4885NOS2 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.